Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M47,117Revenue $M10,659Net Margin (%)15.6Z-Score3.7
Enterprise Value $M50,594EPS $3.7Operating Margin %18.7F-Score8
P/E(ttm))28.6Cash Flow Per Share $5.3Pre-tax Margin (%)17.1Higher ROA y-yY
Price/Book4.610-y EBITDA Growth Rate %8.0Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %2.0Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow11.0y-y EBITDA Growth Rate %-8.3ROA % (ttm)8.2Higher Current Ratio y-yN
Dividend Yield %1.3Insider Buy (3m)2ROE % (ttm)17.2Less Shares Outstanding y-yY
Payout Ratio %45.0Shares Outstanding M453ROI % (ttm)10.6Gross Margin Increase y-yY

Gurus Latest Trades with COV

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
COVDavid Abrams 2014-09-30 Buy 13.4%$82.54 - $91.76
($88.57)
$ 104.0618%New holding, 2620000 sh.2,620,000
COVJohn Paulson 2014-09-30 Add2%$82.54 - $91.76
($88.57)
$ 104.0618%Add 79.93%12,595,000
COVPrivate Capital 2014-09-30 Reduce-0.85%$82.54 - $91.76
($88.57)
$ 104.0618%Reduce -33.88%157,828
COVGeorge Soros 2014-09-30 Sold Out -0.15%$82.54 - $91.76
($88.57)
$ 104.0618%Sold Out0
COVMario Gabelli 2014-09-30 Reduce-0.08%$82.54 - $91.76
($88.57)
$ 104.0618%Reduce -27.49%462,251
COVJohn Paulson 2014-06-30 Buy 2.7%$69.03 - $91.24
($74.56)
$ 104.0640%New holding, 7000000 sh.7,000,000
COVGeorge Soros 2014-06-30 Buy 0.15%$69.03 - $91.24
($74.56)
$ 104.0640%New holding, 227000 sh.227,000
COVJoel Greenblatt 2014-06-30 Sold Out $69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVBill Nygren 2014-06-30 Reduce-1.51%$69.03 - $91.24
($74.56)
$ 104.0640%Reduce -94.09%160,000
COVRobert Olstein 2014-06-30 Sold Out -0.95%$69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVYacktman Focused Fund 2014-06-30 Sold Out -0.62%$69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVYacktman Fund 2014-06-30 Sold Out -0.56%$69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVDonald Yacktman 2014-06-30 Sold Out -0.55%$69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVRay Dalio 2014-06-30 Sold Out -0.03%$69.03 - $91.24
($74.56)
$ 104.0640%Sold Out0
COVJoel Greenblatt 2014-03-31 Buy $66.35 - $72.5
($69.62)
$ 104.0650%New holding, 3746 sh.3,746
COVRay Dalio 2014-03-31 Reduce-0.02%$66.35 - $72.5
($69.62)
$ 104.0650%Reduce -41.8%47,058
COVVanguard Health Care Fund 2013-12-31 Add0.22%$59.82 - $68.42
($65.08)
$ 104.0660%Add 24.79%4,994,700
COVRay Dalio 2013-12-31 Buy 0.04%$59.82 - $68.42
($65.08)
$ 104.0660%New holding, 80858 sh.80,858
COVPrivate Capital 2013-12-31 Reduce-0.8%$59.82 - $68.42
($65.08)
$ 104.0660%Reduce -36.57%244,555
COVHOTCHKIS & WILEY 2013-12-31 Reduce-0.16%$59.82 - $68.42
($65.08)
$ 104.0660%Reduce -46.79%657,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

COV is held by these Gurus:


News about COV:

Articles On GuruFocus.com
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 16 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
Abbott: A Brighter Future Aug 28 2014 
A Strong Candidate for Investor´s Portfolios Aug 12 2014 
The Gabelli Equity Income Fund Second Quarter 2014 Shareholder Commentary Jul 25 2014 
Steven Romick's Top Five Stocks Jul 11 2014 


More From Other Websites
Farallon Capital ups stake in Covidien Dec 19 2014
Covidien Declares Quarterly Cash Dividend Dec 19 2014
Covidien Declares Quarterly Cash Dividend Dec 19 2014
Great Stocks: Mallinckrodt Rebounds, But Is It A Buy? Dec 18 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical... Dec 17 2014
Covidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools:... Dec 17 2014
Covidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools:... Dec 17 2014
Magnetar sells stakes in Covidien Dec 15 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014 Dec 11 2014
Covidien Loses $176M Award in Patent Case Against JNJ Unit Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014 Dec 09 2014
Top Global Stocks: Jazz, Actavis In IBD's World List Dec 08 2014
Medtronic-Covidien Deal Nears Finish Line, Approvals Flow In Dec 08 2014
Form 8.1 – Covidien Dec 05 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK